Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease

the Michael J Fox Foundation LRRK2 Consortium

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To evaluate sex differences and the relative effect of G2019S LRRK2 mutations in Parkinson's disease (PD). Methods: 530 LRRK2 PD carriers and 759 noncarrier PD (idiopathic, IPD) evaluated as part of the Fox Foundation (MJFF) Consortium were included. All participants completed a study visit including information on clinical features, treatment, examination, and motor and nonmotor questionnaires. Clinical features were compared between men and women separately for IPD and LRRK2 PD; and features were compared between IPD and LRRK2 PD separately for men and women. Results: Among IPD: men had higher levodopa equivalency dose (LED), worse activities of daily living and motoric severity but lower complications of therapy (UPDRS-IV). IPD women had higher olfaction and thermoregulatory scores and were more likely to report family history of PD. Among LRRK2 PD: Male predominance was not observed among G2019S LRRK2 cases. Women had worse UPDRS-IV but better olfaction. Among same sex: LRRK2 men and women had better olfaction than IPD counterparts. LRRK2 men demonstrated lower motor and higher cognitive, RBD and thermoregulation scores than IPD men and LRRK2 women had greater UDPRS-IV and rates of dyskinesia. Interpretation: There were clinical differences between sexes with a more severe phenotype in IPD men and more complications of therapy in women. The more severe male phenotype was moderated by LRRK2, with LRRK2 men and women showing less diversity of phenotype. Our study supports that both genetics and sex drive phenotype, and thus trials in LRRK2 and IPD should consider gender stratification in design or analysis.

Original languageEnglish (US)
Pages (from-to)801-810
Number of pages10
JournalAnnals of Clinical and Translational Neurology
Volume4
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Sex Characteristics
Parkinson Disease
Smell
Phenotype
Body Temperature Regulation
Dyskinesias
Levodopa
Activities of Daily Living
Therapeutics
Mutation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease. / the Michael J Fox Foundation LRRK2 Consortium.

In: Annals of Clinical and Translational Neurology, Vol. 4, No. 11, 01.11.2017, p. 801-810.

Research output: Contribution to journalArticle

the Michael J Fox Foundation LRRK2 Consortium. / Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease. In: Annals of Clinical and Translational Neurology. 2017 ; Vol. 4, No. 11. pp. 801-810.
@article{a71c69f88c47431b9a7918702bf5f5ef,
title = "Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease",
abstract = "Objective: To evaluate sex differences and the relative effect of G2019S LRRK2 mutations in Parkinson's disease (PD). Methods: 530 LRRK2 PD carriers and 759 noncarrier PD (idiopathic, IPD) evaluated as part of the Fox Foundation (MJFF) Consortium were included. All participants completed a study visit including information on clinical features, treatment, examination, and motor and nonmotor questionnaires. Clinical features were compared between men and women separately for IPD and LRRK2 PD; and features were compared between IPD and LRRK2 PD separately for men and women. Results: Among IPD: men had higher levodopa equivalency dose (LED), worse activities of daily living and motoric severity but lower complications of therapy (UPDRS-IV). IPD women had higher olfaction and thermoregulatory scores and were more likely to report family history of PD. Among LRRK2 PD: Male predominance was not observed among G2019S LRRK2 cases. Women had worse UPDRS-IV but better olfaction. Among same sex: LRRK2 men and women had better olfaction than IPD counterparts. LRRK2 men demonstrated lower motor and higher cognitive, RBD and thermoregulation scores than IPD men and LRRK2 women had greater UDPRS-IV and rates of dyskinesia. Interpretation: There were clinical differences between sexes with a more severe phenotype in IPD men and more complications of therapy in women. The more severe male phenotype was moderated by LRRK2, with LRRK2 men and women showing less diversity of phenotype. Our study supports that both genetics and sex drive phenotype, and thus trials in LRRK2 and IPD should consider gender stratification in design or analysis.",
author = "{the Michael J Fox Foundation LRRK2 Consortium} and {San Luciano}, Marta and Cuiling Wang and Ortega, {Roberto A.} and Nir Giladi and Karen Marder and Susan Bressman and Rachel Saunders-Pullman",
year = "2017",
month = "11",
day = "1",
doi = "10.1002/acn3.489",
language = "English (US)",
volume = "4",
pages = "801--810",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease

AU - the Michael J Fox Foundation LRRK2 Consortium

AU - San Luciano, Marta

AU - Wang, Cuiling

AU - Ortega, Roberto A.

AU - Giladi, Nir

AU - Marder, Karen

AU - Bressman, Susan

AU - Saunders-Pullman, Rachel

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Objective: To evaluate sex differences and the relative effect of G2019S LRRK2 mutations in Parkinson's disease (PD). Methods: 530 LRRK2 PD carriers and 759 noncarrier PD (idiopathic, IPD) evaluated as part of the Fox Foundation (MJFF) Consortium were included. All participants completed a study visit including information on clinical features, treatment, examination, and motor and nonmotor questionnaires. Clinical features were compared between men and women separately for IPD and LRRK2 PD; and features were compared between IPD and LRRK2 PD separately for men and women. Results: Among IPD: men had higher levodopa equivalency dose (LED), worse activities of daily living and motoric severity but lower complications of therapy (UPDRS-IV). IPD women had higher olfaction and thermoregulatory scores and were more likely to report family history of PD. Among LRRK2 PD: Male predominance was not observed among G2019S LRRK2 cases. Women had worse UPDRS-IV but better olfaction. Among same sex: LRRK2 men and women had better olfaction than IPD counterparts. LRRK2 men demonstrated lower motor and higher cognitive, RBD and thermoregulation scores than IPD men and LRRK2 women had greater UDPRS-IV and rates of dyskinesia. Interpretation: There were clinical differences between sexes with a more severe phenotype in IPD men and more complications of therapy in women. The more severe male phenotype was moderated by LRRK2, with LRRK2 men and women showing less diversity of phenotype. Our study supports that both genetics and sex drive phenotype, and thus trials in LRRK2 and IPD should consider gender stratification in design or analysis.

AB - Objective: To evaluate sex differences and the relative effect of G2019S LRRK2 mutations in Parkinson's disease (PD). Methods: 530 LRRK2 PD carriers and 759 noncarrier PD (idiopathic, IPD) evaluated as part of the Fox Foundation (MJFF) Consortium were included. All participants completed a study visit including information on clinical features, treatment, examination, and motor and nonmotor questionnaires. Clinical features were compared between men and women separately for IPD and LRRK2 PD; and features were compared between IPD and LRRK2 PD separately for men and women. Results: Among IPD: men had higher levodopa equivalency dose (LED), worse activities of daily living and motoric severity but lower complications of therapy (UPDRS-IV). IPD women had higher olfaction and thermoregulatory scores and were more likely to report family history of PD. Among LRRK2 PD: Male predominance was not observed among G2019S LRRK2 cases. Women had worse UPDRS-IV but better olfaction. Among same sex: LRRK2 men and women had better olfaction than IPD counterparts. LRRK2 men demonstrated lower motor and higher cognitive, RBD and thermoregulation scores than IPD men and LRRK2 women had greater UDPRS-IV and rates of dyskinesia. Interpretation: There were clinical differences between sexes with a more severe phenotype in IPD men and more complications of therapy in women. The more severe male phenotype was moderated by LRRK2, with LRRK2 men and women showing less diversity of phenotype. Our study supports that both genetics and sex drive phenotype, and thus trials in LRRK2 and IPD should consider gender stratification in design or analysis.

UR - http://www.scopus.com/inward/record.url?scp=85031665753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031665753&partnerID=8YFLogxK

U2 - 10.1002/acn3.489

DO - 10.1002/acn3.489

M3 - Article

VL - 4

SP - 801

EP - 810

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

SN - 2328-9503

IS - 11

ER -